JP5400381B2 - 発癌の幹細胞融合モデル - Google Patents
発癌の幹細胞融合モデル Download PDFInfo
- Publication number
- JP5400381B2 JP5400381B2 JP2008528229A JP2008528229A JP5400381B2 JP 5400381 B2 JP5400381 B2 JP 5400381B2 JP 2008528229 A JP2008528229 A JP 2008528229A JP 2008528229 A JP2008528229 A JP 2008528229A JP 5400381 B2 JP5400381 B2 JP 5400381B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- cancer
- fusion
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本出願は2005年8月25日に提出した発明の名称「発癌の幹細胞融合モデル」の米国仮出願第60/711,249号に基づいて優先権を主張し、当該出願の全内容を参照することにより取り込まれる。
以下の実験で用いられる実験技術は確立されたもので広く一般に受け入れられている。
A群:8匹の遺伝子導入マウス
GFPで標識した骨髄細胞を単独で、または形質転換された良性ヒトもしくはマウス細胞と組み合わせてマウスに接種する。
実験手順の概要概略
マウスに転移性形質転換ヒト(PC3-M)またはマウス(308 10Gy5または4T1)細胞と、CXCR4受容体の抑制剤とを接種する。必要とされるマウス総数: (4匹/処理) (3処理) (3投与時点) (3実験) = 108匹。
細胞:二つの転移性癌細胞系を使って、ユビキチン抗体の細胞運動を抑制する能力を調べた。PC-3Mはヒト前立腺癌細胞系である。4T1はマウス乳癌細胞系である。両細胞系は10%FBSとグルタマックス(Glutamax)1を添加したDMEM培養液(以下、DMEM培養液)で維持した。
細胞:マウス転移性乳癌細胞系、4T1を使用しユビキチン抗体の転移を抑制する能力を調べた。前記細胞はDMEM培養液中に、前述のプロトコルに記載した培養条件に従って維持した。
1. Auerbach R, Lewis R, Shinners B, Kubal L, Akhtar N. 「血管形成分析:重要概説(Angiogenesis Assays: A Critical Overview)」 Clinical Chemistry 49 (1), 1 Jan. 2003:32-40.
本発明の方法は、対象における腫瘍の移動を抑制するのに用いることができる。脊椎動物の対象、好ましくは哺乳動物、より好ましくはヒトに、腫瘍細胞の移動を抑制するのに有効な量の合成物(compound)を投与する。前記合成物または医薬的に許容しうるその塩は好ましくは医薬組成物の形態で投与される。
Claims (4)
- ヒトを除く対象において、転移性癌細胞の移動に対するユビキチンに対する抗体の効果をスクリーニングする方法であって、
(a)インビボで前記転移性癌細胞をユビキチンに対する抗体と接触させる工程、および
(b)転移性癌細胞の移動が抑制されるかどうかを測定する工程を含む、前記方法。 - 前記抗体は抗体14372および抗体10C2-2から成る群より選択される、請求項1記載の方法。
- インビトロで、転移性癌細胞の移動に対するユビキチンに対する抗体の効果をスクリーニングする方法であって、
(a)前記転移性癌細胞をユビキチンに対する抗体と接触させる工程、および
(b)転移性癌細胞の移動が抑制されるかどうかを測定する工程を含む、前記方法。 - 前記抗体は抗体14372および抗体10C2-2から成る群より選択される、請求項3記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71124905P | 2005-08-25 | 2005-08-25 | |
US60/711,249 | 2005-08-25 | ||
PCT/US2006/033366 WO2007025216A2 (en) | 2005-08-25 | 2006-08-25 | Stem cell fusion model of carcinogenesis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011170717A Division JP5597171B2 (ja) | 2005-08-25 | 2011-08-04 | 腫瘍細胞移動の抑制方法及びこれに用いる薬剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009505664A JP2009505664A (ja) | 2009-02-12 |
JP5400381B2 true JP5400381B2 (ja) | 2014-01-29 |
Family
ID=37772481
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008528229A Expired - Fee Related JP5400381B2 (ja) | 2005-08-25 | 2006-08-25 | 発癌の幹細胞融合モデル |
JP2011170717A Expired - Fee Related JP5597171B2 (ja) | 2005-08-25 | 2011-08-04 | 腫瘍細胞移動の抑制方法及びこれに用いる薬剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011170717A Expired - Fee Related JP5597171B2 (ja) | 2005-08-25 | 2011-08-04 | 腫瘍細胞移動の抑制方法及びこれに用いる薬剤 |
Country Status (16)
Country | Link |
---|---|
US (2) | US8158126B2 (ja) |
EP (2) | EP2363146B1 (ja) |
JP (2) | JP5400381B2 (ja) |
KR (2) | KR101413055B1 (ja) |
CN (2) | CN103212071B (ja) |
AU (2) | AU2006282853B2 (ja) |
BR (1) | BRPI0615081A2 (ja) |
CA (2) | CA2620616C (ja) |
ES (2) | ES2552101T3 (ja) |
HK (1) | HK1161976A1 (ja) |
HU (1) | HUE025948T2 (ja) |
IL (2) | IL189674A (ja) |
RU (1) | RU2404805C2 (ja) |
SG (1) | SG152229A1 (ja) |
WO (1) | WO2007025216A2 (ja) |
ZA (1) | ZA200802512B (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL145546A0 (en) | 1999-04-05 | 2002-06-30 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
US20120295344A1 (en) * | 2006-08-25 | 2012-11-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Stem Cell Fusion Model of Carcinogenesis |
CN103212071B (zh) * | 2005-08-25 | 2017-12-12 | 亚利桑那大学董事会 | 干细胞融合癌发生模型 |
JP2009508875A (ja) | 2005-09-19 | 2009-03-05 | エミスフェアー・テクノロジーズ・インク | N−(5−クロロサリチロイル)−8−アミノカプリル酸二ナトリウム塩の結晶形 |
WO2007120334A2 (en) | 2005-12-15 | 2007-10-25 | Genentech, Inc. | Methods and compositions for targeting polyubiquitin |
CA2710398A1 (en) | 2008-01-18 | 2009-10-15 | Genentech, Inc. | Methods and compositions for targeting polyubiquitin |
CN101760452B (zh) * | 2008-11-18 | 2012-12-19 | 中国科学院上海生命科学研究院 | 一种胚胎干细胞和肿瘤细胞的杂合细胞系及其构建方法 |
US8178307B2 (en) * | 2009-09-02 | 2012-05-15 | National Tsing Hua University | Methods and compositions for detection of lethal cell and uses thereof |
KR20130062264A (ko) | 2010-04-15 | 2013-06-12 | 제넨테크, 인크. | 항-폴리유비퀴틴 항체 및 사용 방법 |
AU2011339929B2 (en) | 2010-12-06 | 2017-05-11 | Tom C. Tsang | Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer |
RU2630637C2 (ru) | 2011-08-05 | 2017-09-11 | Дженентек, Инк. | Анти-полиубиквитиновые антитела и способы применения |
CN110391025A (zh) * | 2018-04-19 | 2019-10-29 | 清华大学 | 一种面向宏微观多维度胃癌早期风险评估的人工智能建模方法 |
US11052041B1 (en) | 2020-10-01 | 2021-07-06 | King Abdulaziz University | Nanotechnology-based nostril drops for relief of respiratory ailments |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0462111A4 (en) * | 1988-12-23 | 1992-07-08 | The Board Of Trustees Of The Leland Stanford Junior University | Homing sequences and their uses |
US6007816A (en) | 1989-03-17 | 1999-12-28 | Fred Hutchinson Cancer Research Center | Methods of using CD44-specific antibodies |
WO1994021294A1 (en) * | 1993-03-19 | 1994-09-29 | Bigner Darell D | Method of treating tumors with antibodies |
CA2235245A1 (en) | 1995-10-17 | 1997-04-24 | Dovetail Technologies, Inc | Low molecular weight cell, bone marrow and immune stimulants |
JP2004507459A (ja) * | 1999-08-25 | 2004-03-11 | アルタレックス コーポレイション | 免疫病態治療用組成物および方法 |
US20050181381A1 (en) | 2003-04-18 | 2005-08-18 | University Of Massachusetts | Prognosis, diagnosis and treatment of bone marrow derived stem cell associated cancer |
CN1302102C (zh) * | 2003-12-29 | 2007-02-28 | 中国医学科学院血液学研究所 | 通过扩增巨核祖细胞和成熟巨核细胞制备巨核细胞制剂的方法及用途 |
US20060033366A1 (en) | 2004-08-11 | 2006-02-16 | Jeffrey Vernon M | Headrest display device |
CN101583273A (zh) * | 2005-07-22 | 2009-11-18 | 加利福尼亚大学董事会 | 肝素组合物和选择素抑制 |
CN103212071B (zh) * | 2005-08-25 | 2017-12-12 | 亚利桑那大学董事会 | 干细胞融合癌发生模型 |
-
2006
- 2006-08-25 CN CN201310075972.2A patent/CN103212071B/zh not_active Expired - Fee Related
- 2006-08-25 CA CA2620616A patent/CA2620616C/en not_active Expired - Fee Related
- 2006-08-25 ES ES11165870.4T patent/ES2552101T3/es active Active
- 2006-08-25 CA CA2808168A patent/CA2808168C/en not_active Expired - Fee Related
- 2006-08-25 HU HUE11165870A patent/HUE025948T2/en unknown
- 2006-08-25 RU RU2008111144/14A patent/RU2404805C2/ru not_active IP Right Cessation
- 2006-08-25 CN CN2006800353702A patent/CN101273124B/zh not_active Expired - Fee Related
- 2006-08-25 US US12/064,745 patent/US8158126B2/en not_active Expired - Fee Related
- 2006-08-25 EP EP11165870.4A patent/EP2363146B1/en not_active Not-in-force
- 2006-08-25 KR KR1020137004050A patent/KR101413055B1/ko active IP Right Grant
- 2006-08-25 KR KR1020087007205A patent/KR101413048B1/ko active IP Right Grant
- 2006-08-25 AU AU2006282853A patent/AU2006282853B2/en not_active Ceased
- 2006-08-25 BR BRPI0615081-0A patent/BRPI0615081A2/pt not_active Application Discontinuation
- 2006-08-25 SG SG200902382-1A patent/SG152229A1/en unknown
- 2006-08-25 ES ES06802407.4T patent/ES2523857T3/es active Active
- 2006-08-25 WO PCT/US2006/033366 patent/WO2007025216A2/en active Application Filing
- 2006-08-25 EP EP06802407.4A patent/EP1924685B1/en not_active Not-in-force
- 2006-08-25 JP JP2008528229A patent/JP5400381B2/ja not_active Expired - Fee Related
-
2008
- 2008-02-21 IL IL189674A patent/IL189674A/en not_active IP Right Cessation
- 2008-03-14 ZA ZA200802512A patent/ZA200802512B/xx unknown
-
2011
- 2011-04-08 AU AU2011201605A patent/AU2011201605B2/en not_active Ceased
- 2011-08-04 JP JP2011170717A patent/JP5597171B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-07 HK HK12102292.7A patent/HK1161976A1/xx not_active IP Right Cessation
- 2012-04-16 US US13/448,112 patent/US8758755B2/en not_active Expired - Fee Related
- 2012-10-16 IL IL222468A patent/IL222468A/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5400381B2 (ja) | 発癌の幹細胞融合モデル | |
Gowing et al. | Ablation of proliferating microglia does not affect motor neuron degeneration in amyotrophic lateral sclerosis caused by mutant superoxide dismutase | |
Wang et al. | Pre-clinical study of human umbilical cord mesenchymal stem cell transplantation for the treatment of traumatic brain injury: safety evaluation from immunogenic and oncogenic perspectives | |
Zhang et al. | Bone metastasis initiation is coupled with bone remodeling through osteogenic differentiation of NG2+ cells | |
CN110499290B (zh) | 一株人尤文肉瘤细胞系 | |
US20140308297A1 (en) | Stem Cell Fusion Model of Carcinogenesis | |
Liang et al. | Deficiency of lipid phosphatase SHIP enables long-term reconstitution of hematopoietic inductive bone marrow microenvironment | |
Lauder et al. | Using methylcholanthrene-induced fibrosarcomas to study tumor immunology | |
Sattiraju et al. | Spatial patterning and immunosuppression of glioblastoma immune contexture in hypoxic niches | |
EP4043554A1 (en) | Production method for vascular endothelial stem cell | |
US20200108091A1 (en) | Gut-protective effect of rig-1/mavs and sting activation | |
Maru et al. | Whole-Body Matter | |
Coazzoli | THE ROLE OF NUMB IN STEM CELL HOMEOSTASIS AND BREAST TUMORIGENESIS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110208 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110506 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110513 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110606 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110613 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110701 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110708 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110804 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120424 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120711 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120719 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120813 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120820 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120910 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120918 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121023 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130212 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130425 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130507 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130516 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130523 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130809 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131001 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131025 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5400381 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |